N. prodotti: 0
Totale ordine: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Kruse V. 1, Van de Wiele C. 2, 4, Maes A. 4, 5, Borms M. 3, Pottel H. 5, Van Belle S. 1, Cocquyt V. 1
1 Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium;
2 Department of Radiology and Nuclear Medicine, University Ghent, Ghent, Belgium;
3 Department of Radiotherapy and Medical Oncology, AZ Groeninge, Kortrijk, Belgium;
4 Department of Nuclear medicine, AZ Groeninge, Kortrijk, Belgium;
5 Subfaculty of Medicine, Catholic University Leuven, Campus Kortrijk, Belgium
PURPOSE: To assess whether outcome in advanced breast cancer patients is related to metabolic response to endocrine therapy determined by FDG-PET.
METHODS: We retrospectively identified 21 consecutive breast cancer patients receiving endocrine therapy for metastatic disease (number of previous therapies 3.6 ±3.5; mean ±SD). All patients had been evaluated with at least 2 FDG-PET’s. The first scan was performed by initiation of endocrine therapy. The second scan was performed after a mean of 3.8 ±1.14 months (m). Seventy-two FDG-avid lesions were identified and followed. The mean change in SUVmax (ΔSUVmax) was calculated per patient.
RESULTS: ΔSUVmax dichotomized using the group median as cut-off (8.6%) was predictive of progression free survival (PFS). The median PFS for the response-group (n=10, median ΔSUVmax -20.9%) was 10.1 m. The median PFS for the progressive disease-group (n = 11, median ΔSUVmax 40.6%) was 6.7 m (log-rank testing p = 0.033).
CONCLUSIONS: Our data suggest that breast cancer patients under hormonal therapy with stable disease on FDG PET have a longer PFS when compared to non-responders. This finding is new, supporting the value of endocrine therapy among patients with advanced breast cancer.